^
Association details:
| Biomarker: | PIK3CA E545K |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
31 - Targeting PI3K Increases The Efficacy Of Anti-PD-1 Antibody In Cervical Cancer
Published date:
09/18/2023
Excerpt:
Here, we report a case that continuous pembrolizumab monotherapy treatment induced a complete remission of a recurrent cervical cancer patient with systemic metastasis and PIK3CA-E545K mutation, implying that PIK3CA mutation is potentially a biomarker for pembrolizumab treatment in cervical cancer.
